مباشر

Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targets FierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal FierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger BioWorldBiggest gainers and losers for May 11-15, 2026 Endpoints NewsDesign Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China BioPharma DiveHøeg fired in latest FDA shakeup; 20 people die after taking Amgen drug Endpoints NewsMerck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule Endpoints NewsThe Supreme Court won't take up drugmakers' IRA cases FierceBiotechNominations now open for Fierce Biotech's 2026 Fierce 15 FierceBiotechRegeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy FierceBiotechVincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators PharmaVoiceRace intensifies to lead next wave of obesity drugs as trial results loom

FierceBiotech ١٨ مايو ٢٠٢٦

Boston Scientific funnels $1.5B into MiRus, with option to buy TAVR system

Acquisitive Boston Scientific is making deals again with a major investment play into a private medtech with an option to snap up exclusive rights to its Transc...

Acquisitive Boston Scientific is making deals again with a major investment play into a private medtech with an option to snap up exclusive rights to its Transcatheter Aortic Valve Replacement system.